close
Enquiry IconContact Us
Logo

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Bile duct cancer is a form of cancer in which epithelial cells are mutated which shows epithelial differentiation in the bile duct. It is type of rare disease.

Furthermore, major key players are focusing on adoption of inorganic strategies such as collaborations, in order to strengthen their product offerings and presence in the global bile duct cancer market

In Mach 2021, QED Therapeutics a biotechnology company, announced that it collaborated with Helsinn Group, a privately owned pharmaceutical group with an extensive portfolio of marketed cancer care, rare disease products, and a broad development pipeline. The collaboration is to co-develop and commercialize Infigratinib, an oral FGFR1-3 selective inhibitor, for patients dealing with cholangiocarcinoma (bile duct cancer).

The global bile duct cancer market is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% over the forecast period (2021-2028).

Figure 1. Global Bile Duct Cancer Market Share (%) in Terms of Value, By Region, 2021

Bile Duct Cancer  | Coherent Market Insights

Rising research and development activities by pharmaceutical companies is expected to aid in the growth of the global bile duct cancer market

For instance, in 2015, Leap therapeutics, developed a humanized monoclonal antibody DKN-01 which is under clinical trial phase I for treatment of bile duct cancer through its anti-neoplastic activity.

Furthermore, in September 2019, Merck Sharp & Dohme Corp, a pharmaceutical company, initiated the investigational clinical trial study on Pembrolizumab (immunotherapy) in combination with Gemcitabine/Cisplatin for the treatment of cholangiocarcinoma (bile duct cancer). The study is currently in Phase 3 clinical trials and is expected to be completed by August 2023.

request-sample

Bile Duct Cancer Market Report Coverage

Report Coverage Details
Base Year: 2020 Market Size in 2021: US$ 185.4 Mn
Historical Data for: 2017 to 2020 Forecast Period: 2021 to 2028
Forecast Period 2021 to 2028 CAGR: 12.8% 2028 Value Projection: US$ 429.6 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment Type: Chemotherapy (Gemcitabine, Cisplatin, Oxaliplatin, Capecitabine, 5 fluorouracil (5-FU)), Targeted Therapy (Pemigatinib, Infigratinib (Phase 3), Ivosidenib (Phase 3)), Immunotherapy (Pembrolizumab (Phase 3)), Others
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
Companies covered:

Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P. and Delcath Systems, Inc.

Growth Drivers:
  • Increasing prevalence of cholangiocarcinoma
  • Increasing drug approvals and launches
Restraints & Challenges:
  • High cost of bile duct cancer treatment 

Figure 2. Global Bile Duct Cancer Market Share (%), by Distribution Channel, 2021

Bile Duct Cancer  | Coherent Market Insights

Global Bile Duct Cancer Market– Impact of Coronavirus (COVID-19) Pandemic- Government Initiatives to Combat COVID-19

COVID-19 pandemic has affected the economy in three main ways; 1) by directly affecting the production and demand; 2) by creating disruptions in distribution channels; and 3) through its financial impact on companies and financial markets

Furthermore, in May 2020, the Government of India announced relief for an amount of US$ 13.3 per person for daily wagers and construction workers for all states and union territories

In June 2020, All of Us Research Program, part of the National Institutes of Health, announced COVID-19 research initiatives through antibody testing. The study collaborators include the Frederick National Laboratory for Cancer Research, supported by the National Cancer Institute, the National Institute of Allergy and Infectious Diseases along with the Centers for Disease Control and Prevention.

Hence, increasing research and development of drugs is expected to drive the cholangiocarcinoma market growth.

Global Bile Duct Cancer Market Restraint

Expensive treatments of bile duct cancer on a global level is expected to hamper the market growth over the forecast period.

According to the data published in UCL School of Pharmacy report 2020, oncology treatment (including chemotherapy, targeted therapy, and others) related costs in the U.K. are approximately 0.1 to 0.15%  of GDP or accounts 20 to 25% for oncology treatments.

High cost associated with the treatment of cholangiocarcinoma patients is expected to hamper the market growth. According to the U.S. National Library of Medicine report 2017, the total cost of treatment for cholangiocarcinoma in year 1997 was US$ 36,460 and US$ 77,753 in 2012.

Key Players

Major players operating in the global bile duct cancer market include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.

Bile duct cancer, also known as cholangiocarcinoma, is a type of cancer that forms in the bile ducts. The symptoms of bile duct cancer may include abdominal pain, yellowish skin, weight loss, generalized itching, and fever.

Increasing prevalence of bile duct cancer has driven the market growth, For instance, according to American Cancer Society report 2018, each year around 8,000 people in the U.S. are diagnosed with cholangiocarcinoma. This includes both intrahepatic (inside the liver) and extrahepatic (outside the liver) bile duct cancers.

Market Dynamics

Key players are focusing on product approvals to strengthen their position in the global bile duct cancer market. In February 2021, Eisai Co., Ltd., a pharmaceutical company, received orphan drug designation for a prospective indication for unresectable biliary tract cancer with FGFR2 gene fusion by the Ministry of Health, Labour and Welfare, Japan (MHLW) for its Fibroblast Growth Factor (FGF) receptor selective tyrosine kinase inhibitor E7090.

Key features of the study:

  • This report provides an in-depth analysis of the global bile duct cancer market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global bile duct cancer market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global bile duct cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global bile duct cancer market

Detailed Segmentation:

  • Global Bile Duct Cancer market, By Treatment Type:
    • Chemotherapy
      • Gemcitabine
      • Cisplatin
      • Oxaliplatin
      • Oxaliplatin
      • 5 fluorouracil (5-FU)
    • Targeted Therapy
      • Pemigatinib
      • Infigratinib (Phase 3)
      • Ivosidenib (Phase 3)
    • Immunotherapy
      • Pembrolizumab (Phase 3)
    • Others
  • Global Bile Duct Cancer market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Bile Duct Cancer market, By Region:
    • North America
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Oxaliplatin
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Oxaliplatin
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Oxaliplatin
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Oxaliplatin
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Oxaliplatin
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment Type
        • Chemotherapy
          • Gemcitabine
          • Cisplatin
          • Oxaliplatin
          • Oxaliplatin
          • 5 fluorouracil (5-FU)
        • Targeted Therapy
          • Pemigatinib
          • Infigratinib (Phase 3)
          • Ivosidenib (Phase 3)
        • Immunotherapy
          • Pembrolizumab (Phase 3)
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
      • By Country/Region
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Incyte Corporation*
      • Company Overview
      • Product Portfolio
      • Financial Overview
      • Key Highlights
      • Market Strategies
    • Eisai Co., Ltd.
    • QED Therapeutics, Inc.
    • Agios Pharmaceuticals, Inc.
    • RenovoRx
    • Ability Pharmaceuticals
    • Imbrium Therapeutics L.P.
    • Delcath Systems, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment Type
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Drivers
    • Restraints
    • Opportunity
    • Impact Analysis
    • Pipeline Analysis
    • Regulatory Scenario
    • Market Trends
    • Key Developments
    • Epidemiology
    • PEST Analysis
    • Brand Analysis
  4. Global Bile Duct Cancer market – Impact of Coronavirus (Covid-19) Pandemic
    • Economic Impact
    • COVID-19 Epidemiology
    • Impact on Clinical Trials and Drug Development
    • Government Initiatives
  5. Global Bile Duct Cancer market, By Treatment Type, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Chemotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
        • Gemcitabine
        • Cisplatin
        • Oxaliplatin
        • Oxaliplatin
        • 5 fluorouracil (5-FU)
    • Targeted Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
        • Pemigatinib
        • Infigratinib (Phase 3)
        • Ivosidenib (Phase 3)
    • Immunotherapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
        • Pembrolizumab (Phase 3)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  6. Global Bile Duct Cancer market, By Distribution Channel, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, 2018 – 2028
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2021 – 2028, (US$ Mn)
  7. Global Bile Duct Cancer market, By Region, 2021 – 2028, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2021 and 2028 (%)
      • Y-o-Y Growth Analysis, For Regions, 2018–2028
    • North America
      • Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Country, 2021 – 2028, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment Type, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2021 – 2028, (US$ Mn)
      • Market Size and Forecast, By Region/Country, 2021 – 2028, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  8. Competitive Landscape
    • Competitive Snapshot
      • Incyte Corporation*
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eisai Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • QED Therapeutics, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Agios Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • RenovoRx
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ability Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Imbrium Therapeutics L.P.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Delcath Systems, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 26 market data tables and 27 figures on "Bile Duct Cancer market” - Global forecast to 2028

FAQgrowicon

Frequently Asked Questions

The global bile duct cancer market size is estimated to be valued at US$ 185.4 million in 2021 and is expected to exhibit a CAGR of 12.8% between 2021 and 2028.
Increasing prevalence of cholangiocarcinoma, drug approvals and launches are expected to drive the market growth over the forecast period.
Chemotherapy segment is expected to hold the major market share, owing to increasing product approvals and launches during the forecast period.
North America holds the largest market share in the market.
Major factors hampering growth of the bile duct cancer market include the high cost of bile duct cancer treatment.
Major players operating in the market include Incyte Corporation, Eisai Co., Ltd., QED Therapeutics, Inc., Agios Pharmaceuticals, Inc., RenovoRx, Ability Pharmaceuticals, Imbrium Therapeutics L.P., and Delcath Systems, Inc.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner

Subscribe Newsletter

Kindly subscribe for our latest news & articles.